

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited
三愛健康產業集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

APPOINTMENT OF EXECUTIVE DIRECTOR
AND
RESIGNATION OF DIRECTORS

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Sanai Health Industry Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Xie Haijing (謝海京) (“**Mr. Xie**”) has been appointed as an executive Director with effect from 28 June 2024.

The biographical details of Mr. Xie are set out as follows:

Mr. Xie, aged 53, currently holds the position of the general manager and chairman of the Group’s subsidiary, Beijing Hangyang Health Technology. Co., Ltd.* (北京航洋健康科技有限公司) (“**Beijing Hangyang**”) and is responsible for the overall management of Beijing Hangyang. For details of acquisition of equity interest in Beijing Hangyang by the Group from Mr. Xie, please refer to the announcement of the Company dated 1 March 2024. Mr. Xie has over 30 years of experience in the health product industry and he has served as the Marketing Manager, Vice President of Marketing, General Manager, and Chairman of Beijing Hangyang. In addition, Mr. Xie has been serving as the president of the Beijing Health Products and Cosmetics Association (北京保健品化妝品協會) since March 2015, responsible for the overall management of the association.

Mr. Xie graduated from the Beijing Economics and Business School (北京商品經濟學院) in the People’s Republic of China (the “**PRC**”) with a diploma in marketing in July 1999.

Mr. Xie has entered into a service contract (the “**Service Contract**”) with the Company in respect of his appointment as an executive Director for a initial term of two years with effect from 28 June 2024, which shall be renewable for a successive term of two years, and may be terminated by either party giving to the other not less than three months’ prior notice in writing, and is subject to retirement from office and re-election at the next following annual general meeting of the Company in accordance with the articles of association of the Company (the “**Articles of Association**”). In addition, Mr. Xie is also subject to the rotational retirement and re-election requirements at the annual general meeting of the Company pursuant to the Articles of Association.

Pursuant to the Service Contract, Mr. Xie is entitled to an annual remuneration of HK\$600,000. Mr. Xie’s remuneration is recommended by the remuneration committee of the Company and determined by the Board with reference to his experience, knowledge, qualification, duties and responsibilities within the Group and the prevailing market conditions. Save as the director’s remuneration disclosed herein, Mr. Xie is not entitled to any other benefits.

Save as disclosed above, as at the date of this announcement, Mr. Xie (i) has no interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (ii) has no relationship with any Directors, senior management or substantial or controlling shareholders of the Company; and (iii) has not held any directorship in listed public companies in Hong Kong or overseas in the last three years preceding the date of his appointment.

Save as disclosed above, as at the date of this announcement, Mr. Xie (i) does not currently hold any other position with the Company or any of its subsidiaries; and (ii) there is no other information that is required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, nor is there any other matter that needs to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to welcome Mr. Xie to join the Board.

RESIGNATION OF DIRECTORS

The Board announces that (i) Mr. Gao Borui (“**Mr. Gao**”) has resigned as an executive Director; and (ii) Mr. Xiu Yuan (“**Mr. Xiu**”) has resigned as a non-executive Director with effect from 28 June 2024 in order to devote more time to their personal endeavours.

Each of Mr. Gao and Mr. Xiu has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation which should be brought to the attention of the Shareholders. The Board is also not aware of any such matters in relation to the resignation of Mr. Gao and Mr. Xiu that need to be brought to the attention of the Shareholders. The Board would like to take this opportunity to thank Mr. Gao and Mr. Xiu for their valuable contributions to the Company during their tenure of office.

By order of the Board
Sanai Health Industry Group Company Limited
She Hao
Executive Director

Hong Kong, 28 June 2024

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing, Mr. Yuan Chaoyang, Professor Zhang Rongqing, Mr. She Hao and Mr. Xie Haijing, and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.

** For identification purposes only*